title: [The impact of researchers loyal to Big Pharma on the ethics and quality of clinical trials in Latin America].
abstract: This article explains the difficulties innovative pharmaceutical firms have in repaying shareholders with attractive dividends. The problem is the result of the expiration of the patents of blockbuster drugs and the difficulties that the firms have in bringing new blockbuster drugs to the market. One of the solutions companies have found has been to accelerate the implementation of clinical trials in order to expedite the commercialization of new drugs. Doing so increases the period in which they can sell drugs at monopoly prices. We therefore discuss how innovative pharmaceutical firms shorten the implementation time of clinical trials in Latin America and the consequences such actions have on the quality of the collected data, the protection of human rights of the subjects of experimentation, and compliance with the ethical principles approved in international declarations.
authors: Departamento de Sociología, University of Texas at Austin, EE.UU.
authors: Antonio
authors: A
authors: Ugalde
authors: Departamento de Salud Internacional, Georgetown University, Washington DC, EE.UU.
authors: Núria
authors: N
authors: Homedes
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics / Q000941:ethics* / Q000592:standards*; D016265:Conflict of Interest / Q000191:economics; D004345:Drug Industry / Q000191:economics / Q000941:ethics*; D028744:Ethics Committees, Research / Q000941:ethics / Q000592:standards; D006805:Human Experimentation / Q000941:ethics; D006806:Human Rights; D006801:Humans; D007258:Informed Consent / Q000941:ethics; D007843:Latin America; D010330:Patents as Topic / Q000941:ethics; D000071220:Pharmaceutical Research / Q000191:economics / Q000941:ethics* / Q000592:standards*; D012108:Research Personnel / Q000191:economics / Q000941:ethics*
keywords: Clinical Trial; Research Personnel; Ethics Committees; Informed Consent; Ethics; Latin America